Singapore, Sept. 15 -- Australia-based Telix Pharmaceuticals has announced that the United States (US) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara(R) (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

Published by HT Digital Content Services with permission from BioSpectrum Asia....